Why the study?
Arterial hypertension is the most prevalent cardiovascular risk factor in sub-Saharan Africa, yet few and mostly small randomized trials have studied antihypertensive treatments in people of African descent living there.
Does a triple low-dose or dual antihypertensive drug combination improve blood pressure control compared to standard of care in adults with untreated uncomplicated arterial hypertension in sub-Saharan Africa?
Does a triple low-dose or dual antihypertensive drug combination improve blood pressure control compared to standard of care in adults with untreated uncomplicated arterial hypertension in sub-Saharan Africa?
The coArtHA trial protocol outlines a study to determine the most effective and cost-effective antihypertensive treatment strategy (dual/triple combination vs standard of care) in sub-Saharan Africa.
Background Arterial hypertension is the most prevalent risk factor for cardiovascular disease in sub-Saharan Africa. Only a few and mostly small randomized trials have studied antihypertensive treatments in people of African descent living in sub-Saharan Africa. MethodsIn this open-label, three-arm, parallel randomized controlled trial conducted at two rural hospitals in Lesotho and Tanzania, we compare the efficacy and cost-effectiveness of three antihypertensive treatment strategies among participants aged ≥18 years. The study includes patients with untreated uncomplicated arterial hypertension diagnosed by a standardized office blood pressure ≥ 140/90mmHg. The trial encompasses a superiority comparison between a triple low-dose antihypertensive drug combination versus the current standard of care (monotherapy followed by dual treatment), as well as a non-inferiority comparison for a dual drug combination versus standard of care with optional dose titration after 4 and 8 weeks for participants not reaching the target blood pressure. The sample size is 1268 participants with parallel allocation and a randomization ratio of 2:1:2 for the dual, triple and control arms, respectively. The primary endpoint is the proportion of participants reaching a target blood pressure at 12 weeks of ≤130/80 mmHg and ≤140/90 mmHg among those aged <65 years and ≥65 years, respectively. Clinical manifestations of end-organ damage and cost-effectiveness at 6 months are secondary endpoints. DiscussionThis trial will help to identify the most effective and cost-effective treatment strategies for uncomplicated arterial hypertension among people of African descent living in rural sub-Saharan Africa and inform future clinical guidelines on antihypertensive management in the region. Trial registrationClinicaltrials.gov, NCT04129840. Registered on 17 October 2019 (https://www.clinicaltrials.gov/).
No takes yet. Share an insight, caveat, or question.
Mapesi et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: